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Objective: This study investigated the role of preoperative chemotherapy in 
squamous cell cancer of the esophagus. Methods: A prospective randomized 
trial was undertaken i  147 patients: 74 received preoperative chemother- 
apy comprising cisplatin and 5-fluorouracil and 73 had surgical therapy 
alone. End points were cancer and therapy-related deaths. Results: Sixty-six 
patients (89%) in the chemotherapy group underwent resection compared 
with 69 (95%) in the control group (p = not significant). Of the 60 patients 
who had resection after completing the chemotherapy rogram, 35 (58%) 
had a significant response, of whom four (6.7%) had a complete pathologic 
response. Postoperative mortality rates were 8.3% and 8.7% in the chemo- 
therapy and control groups, respectively (p = not significant). Significant 
dovalstaging was evident with chemotherapy; curative resections were 
possible in 67% Of these patients compared with 35% in the control group 
(p = 0.0003). T3 and T4 tumors were found in 67% and 91% of the 
chemotherapy and control groups, respectively (p = 0.0002). The respective 
figures for N1 disease were 70% and 88% (t7 = 0.009). An intent-to-treat 
analysis of survival showed no significant difference between the two 
groups. Median survivals were 16.8 and 13 months, respectively (p = 0.17), 
Of those who completed the chemotherapy and resection, responders fared 
better than control patients. Median survivals were 42.2 months and 13.8 
months, respectively (p = 0.003). Median survival (8.3 months) was worse 
for nonresponders than for control patients (p = 0.03). The recurrence 
pattern suggested a significant reduction in locoregional disease with 
chemotherapy. Conclusions: Preoperative chemotherapy was safe and re- 
suited in significant downstaging and an increased likelihood of curative 
resection. Survival was not better than that in the surgery-alone group, but 
responders did fare better than nonresponders. (J Thorac Cardiovasc Surg 
1997;114:210,7) 
A dvances in anesthesia, risk analysis, and opera- tive techniques have led to modest improvement 
in the overall prognosis of esophageal canCer during 
the past decades. I' 2 This lack of significant improve- 
ment is perhaps related to the late stage of presen- 
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tation of most patients and to the difficulty of 
achieving an R 0 resection (absence of residual mi- 
croscopic and macroscopic disease 3) because of 
early cancer spread and close proximity of tumor to 
adjacent mediastinal structures. Studies of disease 
recurrence patterns have demonstrated that both 
local and systemic metastases are common. 4'5 Al- 
though surgery remains the standard treatment for 
esophageal cancer, a variety of combined modality 
treatments have been investigated to induce down- 
staging of tumor, improve local control, treat micro- 
metastases, and ultimately to improve long-term 
survival. Few controlled clinical trials have been 
performed. We investigated the role of preoperative 
chemotherapy in squamous cell carcinoma of the 
esophagus in a prospective randomized controlled 
trial. 
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Methods 
From December 1989 to Janua~' 1995, with approval by 
the institutional review board. 147 patients with histologic 
evidence of squamous cell cancer of the thoracic esopha- 
gus were randomized after informed consent to have 
preoperative chemotherapy (chemotherapy group) or am- 
mediate surgery (control group). Preoperative tumor stag- 
ing and assessment of resectabilitv were performed with 
clinical examination, chest roentgenography, double-con- 
trast barium study, abdominal ultrasonography, and en- 
doscopy and bronchoscopy with flexible scopes. Com- 
puted tomography and endoscopic ultrasonography were 
not readily available and so were not routinely performed. 
Tumor stages were defined as follows: An early tumor was 
shorter than 5 cm. produced low-grade obstruction with- 
out longitudinal axis deviation or sinus formation on 
barium contrast studies, and caused no abnormalities on 
bronchoscopic studies. A moderately advanced rumor was 
longer than 5 cm and caused significant obstruction on 
contrast study. A locally advanced tumor was longer than 5 
cm. caused complete obstruction, angulation, or sinuses 
on barium contrast studies, and/or had a bulge abutting 
from outside on bronchoscopic examination, with the 
carina also being widened in some cases. 
Patients were excluded from the trial if any of the 
following findings were present: nonregiona! lymph node 
metastases or systemic organ metastases: tumor infiltra- 
tion into the trachea or bronchi: poor renal function with 
creatinine clearance less than 1.0 ml. sec or serum creati- 
nine concentration greater than 130 txmol/L: white blood 
cell count less than 3500/txl or granulocyte count less than 
1500)xl; and platelet count less than 100.000//xl. Patients 
were also excluded if they had a history of cancer, except 
when these cancers had been treated and had not recurred 
for at least 5 years. 
Chemotherapy regimen. Chemotherapy consisted of 
two courses of cisplatin and 5-fluorouracil. Patients were 
hydrated before the start of chemotherapy. Forced diure- 
sis with 20% mannitol and intravenous fluid was given for 
the first day. Cisplatin (100 mg/m 2) was given as an 
intravenous infusion over 4 hours on day 1, followed by an 
infusion of 5-fluorouracil (500 mg/m 2per day) over days 1 
to 5. Appropriate antiemetic medications were prescribed. 
Chemotherapy was repeated from days 22 to 26. The 
tumor was then restaged and the operation was performed 
on day 42. 
Evaluation of response to chemotherapy. The tumors 
of all patients who had chemotherapy were restaged 
before surgery. Response was graded as follows: no 
response--progression or less than 50% reduction in the 
size of the tumor, as measured by the product of the 
longest perpendicular diameters assessed by endoscopic 
and radiologic studies, or the appearance of new lesions 
not found at baseline; partial response more than 50% 
reduction in size of tumor measured as just described; 
complete response disappearance of tumor on endo- 
scopic and radiologic examination and no other evidence 
of disease; complete pathologic response--no tumor iden- 
tified on histol0gic examination of surgical specimen after 
surgical resection and no other evidence of disease. 
Responders were patients who had a partial or complete 
response, and nonresponders were those with no re- 
sponse. The side effects of chemotherapy were classified 
according to the recommendations of the World Health 
Organization. 
Surgical techniques. Most patients had a tumor of the 
middle third of the esophagus, and our preferred surgical 
approach was through abdominal and right thoracotomy 
incisions together with mediastinal lymphadenectomy. In 
patients with limited cardiopulmonary reserves, a transhi- 
atal resection was performed with a cervical anastomosis. 
Resection was considered curative when the tumor was 
confined to the esophagus and the adjacent lymph nodes 
were either uninvolved or were less than 2 cm in diameter, 
discrete, and within the vicinity of the primary tumor. 
Both the tumor and the adjacent lymph nodes were 
removed completely. Resection was palliative when the 
tumor had infiltrated beyond the esophagus into medias- 
final organs, with gros lymph node metastases, and when 
part of the tumor was known or likely to have been left 
behind after resection. The various surgical techniques 
have been described previously.6 Neither adjuvant chemo- 
therapy nor radiotherapy was given after the operation. 
Such treatments were only selectively applied when recur- 
rent disease was diagnosed in patients who had good 
performance status. 
Follow-up. Patients were seen monthly for 1 year and 
then at 3-month intervals. At each follow-up, a complete 
physical examination was performed. Appropriate inves- 
tigations including endoscopic, radiologic, and histopatho- 
logic examinations were performed as indicated when 
disease recurrence was suspected. The study end points 
were cancer and therapy-related death. Comparisons of 
survival between groups were calculated from the date of 
randomization. 
Statistical analysis. A sample of 150 patients was 
planned, so that an improvement i n the 2-year survival 
from 30% (current result of surgical resection at the 
beginning of the trial) to 50% could be detected with a 
type I error (c~) of 0.05 and a type II error (/3) of 0.1 
(statistical power of 0.9), two-tailed probability tests being 
used. Statistical differences between groups were deter- 
mined by Student's t test, the Mann-Whitney U test, the )(2 
test, o r Fisher's exact est, where appropriate. Survival was 
calculated with the life table method, and differences 
between groups were compared with the generalized 
Wilcoxon test. All calculations were performed with the 
Statistical Package for the Social Sciences (SPSS-X ver- 
sion 3.1, SPSS, Inc., Chicago, Ill.). 
Results 
A total of 147 patients were randomized for the 
trial, 74 in the chemotherapy group and 73 in the 
control group. The patients comprised 125 men and 
22 women, with a mean age (standard error of the 
mean [SEM]) of 64 (0.8) years. The demographics 
of the two groups of patients are shown in Table I. 
There were no significant differences in age, sex 
distribution, level of tumor, tumor differentiation, 
and estimated stage of tumor on enrollment in the 
trial. 
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Table I. Demography of patients on enrollment into 
trial 
No p 
Chemotherapy chemotherapy Value 
No. 74 73 - -  
Sex (male/female) 63/11 62/11 NS 
Mean age (yr ± SEM) 64 _+ 1.1 63 ± 1.1 NS 
Level of tumor 
Upper third 4 6 
Middle third 61 61 
Lower third 7 5 NS 
Double level 2 1 
Estimation of stage of 
disease 
Early 6 3 
Moderate 46 44 NS 
Locally advanced 22 26 
Differentiation of tumor 
Well 22 26 
Moderate 31 34 NS 
Poor 21 13 
Endoscopic length of 5.2 ± 0.29 5.1 --- 0.33 NS 
tumor (cm _+ SEM) 
Barium study length of 6.1 _+ 0.3 6.3 -+ 0.27 NS 
tumor (cm ± SEM) 
Duration of symptom 8.7 _+ 1.1 8.5 ± 0.9 NS 
(wk + SEM) 
Figures represent number of patients unless otherwise stated. SEM, 
Standard error of the mean; NS, not significant. 
Table II. Summary of treatment 
No 
Chemotherapy chemotherapy 
(n=74) (n=73) 
Surgery 
Resection without chemotherapy - -  69 
Two courses of chemotherapy 60 - -  
and resection 
One course of chemotherapy 6* - -  
and resection 
Bypass 1 4 
Nonoperative 
Two courses of chemotherapy; 1" 0 
refused surgical treatment 
One course of chemotherapy; 6* 0 
stopped treatment 
Figures represent umber of patients. 
*For details refer to text. 
Treatments given to the two patient groups are 
listed in Table II. In the chemotherapy group, 13 
patients did not adhere to the trial protocol. Of 
these patients , one had a complete clinical response 
to chemotherapy and refused surgical treatment. A 
small residual tumor was found, which proved to be 
intraepithelial carcinoma on biopsy. Tumor re- 
Table III. Morbidity of preoperative chemotherapy 
in 74 patients 
Grade* 
1 2 3 4 
Hematologic toxicity 
Anemia 22 19 2 2 
Leukopenia 25 18 0 0 
Thrombocytopenia 6 3 3 0 
Increase in serum creatinine 20 3 1 0 
Nausea/vomiting 34 
Electrolyte disturbance 217 
Figures represent umber of patients. 
*World Health Organization grading. 
tOne patient had life-threatening hyponatremia. 
curred 1 year later and was managed with one 
course of chemotherapy followed by radiotherapy. 
The patient remained in remission 18 months later 
at the time of analysis. Twelve other patients did not 
complete the two courses of chemotherapy, sixof 
whom did not have surgical therapy. Of these six 
patients, five refused further treatment and one died 
of a cerebrovascular accident unrelated to chemo- 
therapy. Of the six patients who underwent surgical 
treatment, one was found to have pulmonary tuber- 
culosis and another had pancytopenia; further che- 
motherapy was thus withheld. The other four pa- 
tients did not complete the two courses of treatment 
because of intolerance to the side effects of chemo- 
therapy. Altogether, 66 of the 74 patients (89%) in 
the chemotherapy group underwent resection com- 
pared with 69 of 73 patients (95%) in the control 
group (19 = NS*). 
The prevalence of chemotherapy toxicity is shown 
in Table III. Only one patient had life-threatening 
hyponatremia. Nausea and vomiting were common 
but fairly well tolerated with antiemetic medica- 
tions. 
The 60 patients in the chemotherapy group who 
completed the two courses of chemotherapy lus 
resection were compared with 69 patients in the 
control group who underwent resection. The types 
of resections are listed in Table IV. Middle-third 
tumors were most prevalent, and a Lewis-Tanner 
esophagectomy was the most common surgical pro- 
cedure. A thoracotomy was used for resection in 53 
patients (88%) in the chemotherapy group com- 
pared with 59 (86%) in the control group (p = NS). 
Curative resections were possible in 40 patients 
(67%) in the chemotherapy group and in 24 (35%) 
*NS - Not significant. 
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Table IV. Types of resection 
Chemotherapy No chemotherapy 
(n = 60) (n = 69) 
Lewis-Tanner operation 45 
Three-phase esophagectomy 7 
Transhiatal esophagectomy 4 
Split-sternum esophagectomy 3 
Esophagogastrectomy 1 
42 
15 
7 
3 
2 
Figures represent number of patients. 
of the control group (p = 0.0003). Operative TNM 
staging is shown in Table V. Earlier T stage and NO 
disease were more common in the chemotherapy 
group than in the control group. Perioperative mor- 
bidity and mortality are shown in Table VI. No 
significant differences between groups were found. 
All deaths but one in the chemotherapy group were 
due to pneumonia. This single patient had a hemo- 
thorax necessitating reexploration for hemostasis 
and subsequently died of pneumonia. Four of the six 
deaths in the control group were attributed to 
pneumonia. One other patient died of myocardial 
infarction and one patient had cerebral metastases 
not detected before the operation and died of this 
malignant disease. 
Response to chemotherapy was assessed in the 60 
patients who completed two courses of chemother- 
apy and had pathologic examination of the resected 
specimen. Complete pathologic response was seen 
in four patients, complete clinical remission in four, 
partial response in 27, and no response in 25. 
Preoperative characteristics of responders and non- 
responders are compared in Table VII. Responders 
had an earlier stage of disease and shorter tumor 
length on admission than did nonresponders. 
At a median follow-up time (SEM) of 17 (1.3) 
months, 29 (48%) patients in the chemotherapy 
group and 50 (72%) in the control group have 
recurrent disease (p = 0.005). Patterns of recur- 
rence are shown in Table VIII. The mean times 
(SEM) to recurrence were 8 (1.4) months and 9.7 
(1.0) months in the chemotherapy and control 
groups, respectively (p = NS). 
Of the discharged patients, 30 patients in the 
chemotherapy group and 51 in the control groups 
had died at the time of analysis, 28 and 50, respec- 
tively, of tumor-related causes. 
Actuarial analyses of survival are shown in Figs. 1 
to 4. An intent-to-treat nalysis of the 147 patients 
enrolled in the trial showed no significant difference 
between the chemotherapy and control groups. Me- 
dian survivals were 16.8 and 13 months, respectively 
Table V. TNM staging in patients who underwent 
resection 
Chemotherapy No chemotherapy 
(n = 60) (n - 69) p Value 
0.0002 T stage 
TO * 4 0 
T1 8 2 
T2 8 4 
T3 27 24 
T4 13 39 
N stage 
NO* 18 8 
N1 42 61 
M stage 
M0 60 69 
M1 0 0 
Group staging 
Stage 0* 4 0 
Stage I 6 1 
Stage IIa 8 7 
Stage IIb 5 2 
Stage III 37 59 
0.009 
NS 
0.009 
Figures represent number of patients. 
*Four patients had complete pathologic response on resected specimens. 
Table VL Morbidity and mortality after resection 
No 
Chemotherapy chemotherapy 
(n = 60) (n - 69) p Value 
Blood loss (ml -+ SEM) 795 _+ 58 733 -+ 30 NS 
Operating time 223 _+ 5.6 221 + 5.5 NS 
(min _+ SEM) 
Postoperative trache- 10 (17%) 21 (30%) NS 
ostomy 
Postoperative ntila- 14 (23%) 22 (32%) NS 
tion 
Cardiovascular compli- 20 (30%) 18 (26%) NS 
cations* 
Pulmonary complica- 10 (17%) 11 (16%) NS 
tionst 
Wound infection 4 (7%) 7 (10%) NS 
Anastomotic leakage 3 (5%) 0 (0%) NS 
Thirty-day mortality 0 4 (5.8%) NS 
Hospital mortality 5 (8.3%) 6 (8.7%) NS 
Figures represent umber of patients (%) unless otherwise stated. NS, Not 
significant. 
*Cardiovascular complications include arrhythmia, heart failure, and 
myocardial infarction. 
tPulmonary complications include bronchopneumonia and respiratory 
failure. 
(p = 0.17) (Fig. 1). The actuarial 2-year survivals 
were 44% and 31%, respectively (p = 0.13). When 
the 60 patients who completed the chemotherapy 
course and underwent resection were compared 
with the 69 patients in the control group who 
underwent resection, the median survivals were 16.2 
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Fig. 1. Actuarial survival curves of 74 patients who had 
chemotherapy and 73 patients in the control group (p = 
0.17). 
Table VII. Characteristics of responders versus 
nonresponders 
Responders Nonresponders 
(n = 35) (n = 25) p Value 
Age (yr) 64 + 1.6 65 _+ 1.5 NS 
Sex (male/female) 28:7 22:3 NS 
Level of tumor 
Upper third i 3 
Middle third 32 17 
Lower third 2 4 NS 
Double tumor 0 1 
Preoperative estimate of 
stage of tumor 
Early 6 0 
Moderate 23 12 0.005 
Locally advanced 6 13 
Differentiation of tumor 
Well 12 6 
Moderate 12 12 NS 
Poor 11 7 
Endoscopic length of 4 + 0.3 6 ± 0.6 0.003 
tumor (cm ± SEM) 
Duration of symptoms 7.5 -- 1.2 8.4 ± 2.1 NS 
(wk ± SEM) 
Figures represent number of patients unless otherwise stated. SEM, 
Standard error of the mean; NS, not significant. 
months and 13.8 months, respectively (p = 0.4) (Fig. 
2). The respective median survivals for responders 
and control patients were 42.2 months and 13.8 
months (p = 0.003). Nonresponders had a worse 
median survival (8.3 months) than control subjects 
(p = 0.03) (Fig. 3). Actuarial 2-year survivals for 
responders, control patients, and nonresponders 
were 59%, 33%, and 23%, respectively. The hazard 
ratio for control patients over responders was 1.6 
(95% confidence interval 1.2 to 2.2). Survival of 
100 
80 
60 
40 
20 
0 
Percent surviving 
\ 
L~L chemotherapy n=60 
control n=69 
0 12 24 36 48 60 72 84 
Months 
Fig. 2. Actuarial survival curves of 60 patients who com- 
pleted chemotherapy and resection and 69 patients in the 
control group who had resection (p = 0.4). 
Table VII1. Patterns of recurrent disease after 
resection 
No 
Chemotherapy chemotherapy 
(n = 60) (n = 69) p Value 
No. with recurrence 29 50 0.005 
Locoregioual only 7 21 0.01 
Distant only 12 19 0.3 
Locoregional and 10 10 0.7 
distant 
Figures represent umber of patients. 
patients in the chemotherapy group who had cura- 
tive resections was longer than though not signifi- 
cantly different from that of the control group who 
had curative resections; median survival figures were 
42 months and 28 months, respectively. When pa- 
tients who had palliative resections were compared, 
those in the chemotherapy group had shorter sur- 
vival times; median survival figures were 8 months 
and 13 months, respectively (p = 0.03) (Fig. 4). 
Discussion 
We have demonstrated in this prospective random- 
ized controlled trial that preoperative chemotherapy 
was well tolerated and was not associated with 
increased perioperative morbidity and mortality. 
Significant downstaging and more apparently cura- 
tive resections were possible. Chemotherapy, how- 
ever, did not result in better long-term survival than 
surgical resection alone. Responders to chemother- 
apy lived significantly longer than did patients un- 
dergoing surgery alone, but at the expense of the 
nonresponders, whose life span was significantly 
shorter than that of patients undergoing surgery 
alone. 
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Fig. 3. Actuarial survival curves of responders, nonre- 
sponders, and control groups. Responders versus control, 
p = 0.003; nonresponders versus control, p = 0.03. 
Induction chemotherapy given before surgery has 
theoretic advantages. Because it may improve local 
control, more subsequent R0 resections may be 
achieved. Micrometastases can also be managed, 
and patients who responded can be identified for 
postoperative adjuvant therapy. On the other hand, 
nonresponders would have a delay in surgical ther- 
apy and would be exposed to potentially toxic and 
expensive treatment. 
Various phase II studies have investigated the 
role of preoperative chemotherapy] Few random- 
ized controlled trials have been performed, and the 
number of patients recruited was limited, s-I1 All the 
chemotherapeutic regimens were cisplatin based, 
and no cisplatin-based regimen was found to be 
better than another. In all four prospective random- 
ized trials, chemotherapy was generally well toler- 
ated and was not associated with increased periop- 
erative morbidity and mortality. In only one study 
was chemotherapy associated with drug-related 
deaths, postoperative s ptic and pulmonary compli- 
cations, and operation-related mortality. 9 In an- 
other series one patient also died of leukopenia nd 
sepsis. I° Overall, a major response was seen in 
approximately 50% of patients. Complete patho- 
logic response was seen in fewer than 10% of 
patients. 
In keeping with these trials, the present study 
showed that chemotherapy was safe and did not 
cause drug-related mortality. Postoperative compli- 
cations were also similar. The overall response rate 
was 58% (35/60), and complete pathologic response 
was seen in only 6.7% (3/60) of patients. T and N 
stages were downstaged to a significant degree, 
although the overall resectability rate was not im- 
1 O0 
80 
60 
4o 
20 
0 
Percent surviving 
L • _  chemotherapy (curative) n=40 
control (curative)n=24 
chemotherapy (palliative)n=20 
control (palliative)n=45 
12 24 36 48 60 72 84 
Months 
Fig. 4. Actuarial survival curves of patients with chemo- 
therapy and control groups stratified into curative and 
palliative resections. Chemotherapy (curative) versus con- 
trol (curative), p = 0.22; chemotherapy (palliative) versus 
control (palliative), p = 0.03. 
proved over that of the control group. This could be 
explained by our policy of resecting even tumors of 
very advanced stage. The proportion of patients who 
underwent curative resections was significantly 
higher in the chemotherapy group, and in this group 
the survival was better, but not significantly so, than 
in the curative resection group without chemother- 
apy. 
On follow-up, the recurrence rate in the chemo- 
therapy group was significantly lower than that in 
the control group. The recurrence pattern suggested 
a significant reduction in locoregional disease. Over- 
all, the prevalence of distant recurrences was not 
significantly reduced. 
Overall survival advantages have not been dem- 
onstrated in the four prospective trials, s-ll Respond- 
ers to chemotherapy, however, had longer survival 
times. 8-1° In one study, patients responding to che- 
motherapy had prolonged survival (median > 20 
months) when compared with either nonresponders 
(median 6.2 months) or patients undergoing surgical 
treatment only (median 8.6 months). 8 The survival 
advantage of responders was reaffirmed in the 
present study. We also showed that this gain in 
survival was at the expense of those who did not 
respond to chemotherapy, whose survival was even 
worse than that of the control group. 
The identification of responders to chemotherapy 
is clearly of clinical importance. Administration of 
chemotherapy to those who do not respond delays 
surgical treatment and leads to worse survival. In 
this study, responders had an earlier stage of disease 
and a shorter primary tumor. The relationship of 
chemoresponsiveness to earlier stage of disease was 
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also suggested in another study in which a weight loss 
of less than 10% was significantly correlated with 
response, s Aside from clinical features, techniques of 
in vitro chemosensitivity testing, flow cytometric DNA 
analysis, and immunohistochemical st ining of prod- 
ucts of gene expression on biopsy materials have been 
explored as predictors of response. ~1-15 So far no 
reliable method exists that can predict responsiveness 
to select patients for treatment. 
Our study is the largest randomized controlled 
series published so far on preoperative chemother- 
apy versus surgery alone. It includes only patients 
with squamous cell cancers, and it also has the 
advantage of being undertaken i a single institu- 
tion. Single-center t ials have the fewest variations 
in surgical and anesthetic techniques and perioper- 
ative management. Histologic assessment was also 
carried out by a small group of dedicated patholo- 
gists, allowing the fewest possible variations in stag- 
ing method. 
Multiinstitutional trials do have the advantage of
recruiting sutficient numbers of patients within a 
short time. Two such randomized trials are in 
progress. The Intergroup Trial (protocol 0013) in 
America has accrued more than 350 patients of an 
intended intake of 450. This trial compares surgery 
alone with three courses of cisplatin and 5-fluoro- 
uracil followed by surgery; responders then receive 
two more courses of chemotherapy. 16 The MRC 
trial in the United Kingdom (protocol OE02), which 
planned to recruit 800 patients, has already entered 
434 patients ince 1992) 7 It is hoped that these 
large-scale trials will shed more light on this impor- 
tant question. 
Evidence is now in hand that chemotherapy given 
with concurrent radiotherapy is superior to chemo- 
therapy alone in esophageal cancer. 18 Up to a 40% 
complete response rate could be achieved, although 
toxicities could be substantial nd distant failures 
remain a problem. 19' 2o One recent randomized trial 
has shown for the first time that preoperative che- 
moradiation resulted in a survival advantage com- 
pared with surgery alone for adenocarcinoma of the 
esophagus. 2~So far no survival advantage could be 
proved for patients with squamous cell cancer. Ex- 
ploring this type of multimodality treatment further, 
we have begun another prospective randomized trial 
at our institution comparing preoperative chemora- 
diotherapy with surgery alone. 
In summary, we have shown that preoperative che- 
motherapy resulted in significant tumor downstaging 
and increased the rate of R 0 resections. A survival 
advantage, however, was seen only in those who had 
responded to chemotherapy, whose tumors were of an 
earlier stage. The trial did suggest a trend for survival 
advantage for patients who had preoperative chemo- 
therapy. Perhaps if more patients had been recruited, 
a difference in comparison with the control group may 
have become vident. Multimodality reatment should 
be explored further in the form of chemoradiotherapy. 
It is of vital importance to have reliable predictors of 
response to such treatment, so that better survival 
can be achieved in selected patients without sub- 
jecting others to unnecessary, potentially toxic 
and expensive treatments. 
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